PEPCID
LOE ApproachingNDAORALTABLET
Approved
Oct 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PEPCID (famotidine) is an oral H2-receptor antagonist approved in 1986 for treating acid-related gastrointestinal conditions. It reduces gastric acid secretion and is indicated for peptic ulcer disease, GERD, and acid reflux management. The drug works by competitively blocking histamine H2 receptors on gastric parietal cells.
$0.836MPart D
LOE ApproachingDeclining
Loss of exclusivity is imminent; the brand team is likely focused on managed care retention and generic transition planning rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PEPCID offers limited career growth opportunity given its LOE-approaching status and minimal linked job openings (0). Roles tend to focus on managed decline, generic partnership, and market access rather than product innovation or expansion.
Brand ManagerGeneric Transition Manager
Worked on PEPCID at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.